ClinicalTrials.gg
CompletedNCT06191926Updated Jan 8, 2024

Diagnostic Performance of Shear Wave Dispersive Imaging in Breast Lesions: Comparison With Shear Wave Elastography

An observational study in Breast Diseases, sponsored by Korea University Ansan Hospital. Completed at 1 site in Korea, Republic of. Open to female participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by Korea University Ansan Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
594
Ages
20 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Breast Diseases with a site in Korea, Republic of — 2 open to participants now, 5 under way, 4 of them phase 3. Breast Diseases · Korea, Republic of.

Started
2020
with 1 other
Observational
2 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Korea University Ansan Hospital

Among the 12 studies in Breast Diseases with a site in Korea, Republic of, this one is one of 2 that started in 2020, is one of 2 observational ones, and was the 11th registered.

Breast Diseases

148 studies on the registry are indexed under Breast Diseases; 26 are open to participants now.

Browse Breast Diseases studies →

Open to participants now

2 of the 12 studies in Breast Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 20 Breast Diseases studies recruiting now, 14 (70%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 20 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Breast Diseases with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Human soft tissue such as breast tissue has viscoelasticity property. However, most ultrasound has only been measured for elasticity and viscosity has been neglected. Shear wave elastography (SWE) is a ultrasound technique that quantifies tissue elasticity. Shear wave dispersion (SWD) imaging is a newly developed ultrasound technique that evaluates the dispersion slope of shear waves, which is related to the viscosity of biological tissues. The goal of this retrospective study was to compare diagnostic performance between SWE and SWD to distinguish benign from malignant breast masses and to investigate additional role of SWD. Using histological diagnosis of breast lesions as a standard reference, quantitative indices of SWE and SWD were evaluated to diagnose breast cancer, and the diagnostic performance of SWE and SWD was compared.

Read the detailed description

This retrospective study was approved by our institutional review board, which waved the requrement for informed consent. The investigators obtained quantitative parameters of SWE and SWD of solid breast lesions before biopsy. The investigators measured average tumor elasticity and tumor-to-fat elasticity ratio on SWE and average tumor dispersion and tumor-to-fat ratio and on SWD from each breast lesion. Diagnostic performance of SWE and SWD was compared using the area under the curve (AUC), sensitivity, specificity, and accuracy.

03

Conditions studied

  • Breast Diseases

Browse trials for

04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population should fulfill the following criteria as follows:(a) histologically confirmed breast lesions and (b) shear wave elastography and dispersion ultrasound performed before biopsy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with histological results

Exclusion criteria

Exclusion Criteria:

  • patients without histological results
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
594 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testultrasound

    Shear-wave elastography and shear-wave dispersion ultrasound to evaluate the diagnostic performance of solid breast lesions for the diagnosis of breast cancer

06

What researchers measure

Primary outcomes

  1. Elastography and dispersion parameters to determine benign or malignant tumors

    The elastography and dispersion ultrasound parameter values correlated with histological results.

    Time frame: baseline, pre-biopsy

07

Study locations

1 site
  • Bo Kyoung Seo
    Ansan, 15355, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Aug 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2023
First posted
Jan 5, 2024
StartActual
Aug 1, 2020
Primary completionActual
Aug 31, 2021
CompletionActual
Nov 30, 2023
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06191926
Lead sponsor
Korea University Ansan Hospital
Responsible party
Bo Kyoung Seo (Professor, Korea University Ansan Hospital) — Principal investigator
First posted
Jan 5, 2024
Start date
Aug 1, 2020
Primary completion
Aug 31, 2021
Completion
Nov 30, 2023
Last update
Jan 8, 2024

Study contacts

Bo Kyoung Seo, MD, PhD
principal investigator · Korea University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion